Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURMOUNT-MAINTAIN: Tirzepatide for Maintenance of Body Weight Reduction
NCT06047548Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2023
- Primary completion
- Jan 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tirzepatide in obesity (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percent Maintenance of Body Weight (BW) Reduction Achieved during the 60-Week Weight Loss Period at Week 112. Started Sep 2023; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06047548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06047548.